Braveheart secures $185M to advance challenger to Bristol Myers heart drug

BioPharma Dive Oncology | |

<p>The startup is advancing a drug licensed from China&rsquo;s Hengrui Pharma that it claims could be &ldquo;best-in-class&rdquo; among a group of similar treatments for hypertrophic cardiomyopathy.</p>

Topics: blood-cancer, cervical-cancer, breakthrough-drugs